Header Logo

Connection

HOWARD WEINER to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications HOWARD WEINER has written about Multiple Sclerosis.
HOWARD WEINER
Connection Strength
9.248
Multiple Sclerosis
  1. Glial Activity Load on PET Reveals Persistent "Smoldering" Inflammation in MS Despite Disease-Modifying Treatment: 18 F-PBR06 Study. Clin Nucl Med. 2024 Jun 01; 49(6):491-499.
    View in: PubMed
    Score: 0.639
  2. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
    View in: PubMed
    Score: 0.495
  3. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. J Neuroimaging. 2018 01; 28(1):36-47.
    View in: PubMed
    Score: 0.412
  4. Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017 11 17; 8(1):1600.
    View in: PubMed
    Score: 0.410
  5. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics. 2013 Jan; 10(1):77-88.
    View in: PubMed
    Score: 0.292
  6. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.264
  7. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):75-9.
    View in: PubMed
    Score: 0.236
  8. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov. 2008 Nov; 7(11):909-25.
    View in: PubMed
    Score: 0.219
  9. Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis. Mult Scler. 2026 Aug; 32(9):972-984.
    View in: PubMed
    Score: 0.186
  10. Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis. Cell Rep. 2026 Jun 23; 45(6):117417.
    View in: PubMed
    Score: 0.185
  11. Meta-analysis identifies common gut microbiota associated with multiple sclerosis. Genome Med. 2024 07 31; 16(1):94.
    View in: PubMed
    Score: 0.163
  12. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nat Commun. 2024 May 20; 15(1):4297.
    View in: PubMed
    Score: 0.161
  13. Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2023 11; 10(6).
    View in: PubMed
    Score: 0.154
  14. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023 08; 253:109688.
    View in: PubMed
    Score: 0.151
  15. Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population. PLoS One. 2022; 17(12):e0279132.
    View in: PubMed
    Score: 0.146
  16. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis. Microbiome. 2022 10 17; 10(1):174.
    View in: PubMed
    Score: 0.144
  17. Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets. Genome Biol. 2022 06 07; 23(1):127.
    View in: PubMed
    Score: 0.140
  18. Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Mult Scler Relat Disord. 2022 Jun; 62:103793.
    View in: PubMed
    Score: 0.139
  19. Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome. Nat Commun. 2021 12 06; 12(1):7078.
    View in: PubMed
    Score: 0.136
  20. Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Mult Scler Relat Disord. 2022 Jan; 57:103333.
    View in: PubMed
    Score: 0.135
  21. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.128
  22. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.128
  23. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.124
  24. Serum antibodies to phosphatidylcholine in MS. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.122
  25. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Oct; 267(10):2790-2796.
    View in: PubMed
    Score: 0.122
  26. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.122
  27. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. J Neuroimaging. 2020 03; 30(2):212-218.
    View in: PubMed
    Score: 0.119
  28. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.117
  29. Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors. Sci Rep. 2019 08 28; 9(1):12460.
    View in: PubMed
    Score: 0.116
  30. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.116
  31. A pharmacogenetic study implicates NINJ2 in the response to Interferon-? in multiple sclerosis. Mult Scler. 2020 08; 26(9):1074-1082.
    View in: PubMed
    Score: 0.114
  32. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.112
  33. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019 10; 25(12):1605-1617.
    View in: PubMed
    Score: 0.109
  34. 18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis. Clin Nucl Med. 2018 Sep; 43(9):e289-e295.
    View in: PubMed
    Score: 0.108
  35. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.102
  36. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
    View in: PubMed
    Score: 0.101
  37. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.098
  38. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.098
  39. The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson. J Neurol. 2017 Apr; 264(4):817-828.
    View in: PubMed
    Score: 0.095
  40. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2017 May; 127(5):396-403.
    View in: PubMed
    Score: 0.093
  41. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. J Autoimmun. 2016 08; 72:8-18.
    View in: PubMed
    Score: 0.092
  42. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. J Neuroinflammation. 2015 Dec 30; 12:245.
    View in: PubMed
    Score: 0.090
  43. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Ann Neurol. 2016 Feb; 79(2):178-89.
    View in: PubMed
    Score: 0.090
  44. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.089
  45. Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. Circ Res. 2015 Oct 09; 117(9):779-92.
    View in: PubMed
    Score: 0.088
  46. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology. 2014 Dec 09; 83(24):2219-26.
    View in: PubMed
    Score: 0.083
  47. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.082
  48. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology. 2014 Jun 17; 82(24):2173-9.
    View in: PubMed
    Score: 0.080
  49. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.080
  50. Insights into multiple sclerosis provided by non-coding RNAs: meeting summary from the symposium 'non-coding RNAs in autoimmune disorders of the central nervous system' on 5 April 2013 in Warsaw, Poland. Mult Scler. 2014 Oct; 20(11):1439-42.
    View in: PubMed
    Score: 0.079
  51. Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE. Exp Neurol. 2014 May; 255:63-70.
    View in: PubMed
    Score: 0.079
  52. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.077
  53. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013; 8(3):e59707.
    View in: PubMed
    Score: 0.074
  54. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.072
  55. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.068
  56. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.065
  57. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.064
  58. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.064
  59. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol. 2009 Oct; 30(9):1731-9.
    View in: PubMed
    Score: 0.058
  60. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.057
  61. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb; 66(2):234-7.
    View in: PubMed
    Score: 0.056
  62. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.055
  63. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.053
  64. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1988 Apr 01; 167(4):1313-22.
    View in: PubMed
    Score: 0.053
  65. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev. 1987 Dec; 100:307-32.
    View in: PubMed
    Score: 0.051
  66. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol. 2007 Nov-Dec; 28(10):1956-63.
    View in: PubMed
    Score: 0.051
  67. Cop 1 therapy for multiple sclerosis. N Engl J Med. 1987 Aug 13; 317(7):442-4.
    View in: PubMed
    Score: 0.050
  68. Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential? Neurotherapeutics. 2007 Jul; 4(3):485-98.
    View in: PubMed
    Score: 0.050
  69. Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases. Clin Immunol Immunopathol. 1985 Nov; 37(2):163-71.
    View in: PubMed
    Score: 0.044
  70. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985 May 30; 312(22):1405-11.
    View in: PubMed
    Score: 0.043
  71. Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. J Neuroimaging. 2004 Jul; 14(3 Suppl):46S-53S.
    View in: PubMed
    Score: 0.041
  72. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27; 308(4):173-80.
    View in: PubMed
    Score: 0.037
  73. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.026
  74. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med. 2014 Oct; 20(10):1147-56.
    View in: PubMed
    Score: 0.021
  75. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol. 1991 Jan; 29(1):33-40.
    View in: PubMed
    Score: 0.016
  76. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987 Jan 08; 316(2):67-72.
    View in: PubMed
    Score: 0.012
  77. Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980 Jul 17; 303(3):125-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.